Nanobiotechnology and Nanomedicine Companies

 

(Links listed alphabetically)

 
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | All
 

Showing results 51 - 75 of 170

 
CYTOO focuses on innovative products for the life science research market with an emphasis in cell based assays, high content analysis and cell screening. The company develops, manufactures, and distributes products that make cellular analysis robust and reliable by drastically decreasing cell variability.
Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates.
Applies nanotechnology to the design and manufacture of pumps, coatings and micro-needle arrays.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company also has developed a microfabricated nanopore device for the sustained release of therapeutic agents.
The company's NLP technology produces a generation of particles which retains the strength of the Dermazone Solutions' (SDMC) technologies, but includes the ability to produce particles of 60 nanometers to 150 nanometers which are optically clear. The use of this generation of lipid-based particle delivery system provides the ability to control the size of the final particle by controlling the number of NLPs used to assemble the finished particle. This system maintains very high loading capacity of passenger molecules and uses only safe, all natural ingredients to form both the NLPs and the final delivery system.
The company's proprietary NanoCrystal® technology can enable formulation and improve compound activity and final product characteristics for poorly water-soluble compounds.
Endomagnetics was founded to solve healthcare challenges through the application of advanced magnetic sensing technology.
Serving as a contract research organization, Endotherm Life Science Molecules is a provider of medicinally relevant compounds for the discovery and development of novel small molecule drugs. The product range includes focused compound libraries, building blocks and reagents for the development of biochemical assays (fluorescent and bioluminescent dyes).
EnGeneIC aims to revolutionize the treatment of cancer by targeted delivery of drugs or siRNAs using the same versatile nano-sized delivery vehicle to address the complexities found in cancer cells.
The company is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.
Fluxion develops cellular analysis tools in the pharmaceutical, biotech and research industries. The company has developed a proprietary microfluidic platform which enables precise cellular manipulation, rapid low-volume compound addition, environmental control and software-based data acquisition.
Develops a family of nanocomposite materials designed to increase mechanical performance in medical applications.
Bionanotechnology and microfluidics provide the foundations for GeneFluidics' testing platform. The use of bionanotechnology drives high signal to noise ratios (sensitivity), while the incorporation of microfluidics permits operational simplicity.
The company is developing therapeutic immunotherapy by incorporating virus-specific immunogenic DNA into nanoparticles.
Genovis has a broad knowledge within physics, biology and biochemistry and offers nanoparticles as tools in medical imaging and for in vitro/in vivo transfections. We have developed a new category of nanoparticles that generate a contrast effect in more than one type of medical imaging technique and offer customer made nanoparticles which besides the particles per se also include method development and services in the form of pre-studies that are specifically adapted to the individual needs of the customer.
Grapheal makes embedded and wearable biosensors, digital by design, minimalistic in components, with capabilities to dose biomarkers and detect pathogens anywhere with a simple smartphone.
The company is a leader in life science fluidics, microfluidics, and optics, offering a three-fold advantage to customers by bringing optofluidic paths to life with strategic partnerships, breakthrough solutions, and proven expertise.
The company's focus is on the rapidly emerging field of nanobiotechnology with an emphasis on the early detection and localization of cancer and other human diseases. Their technologies also hold the promise of providing image-guided therapy for the treatment of these diseases, as well as providing new methods for therapeutic intervention.
The company's RiboLace micro- and nanoparticle technology is embedded in two products: for better RNA-seq experiments and for better Ribosome Profiling experiments.
(German language site) The company is a Contract Research Organisation for the development and improvement of advanced cell culture systems for industrial drug screening applications, biomaterial testing and pharma-toxicological research.
A spin off founded to commercialize FDEC FET nano sensor technology invented at Arizona State University.The novel nano sensor technology is capable of exponential capacitive transduction for ultra high sensitivity molecular detection, coupled with exceptional selectivity.
Inanovate creates nano-scale surface structures through a unique and proprietary process capable of nano-meter precision in a time and cost effective way. Leveraging this unique platform and expertise, Inanovate is developing nano-structured biochip substrates to facilitate the next generation in biochip technology.
The company has active internal drug discovery programs focused on the identification of novel small molecule drugs for oncology, inflammation, HIV and diabetes.
The company is engaged in R&D and production of nanomaterials and nanomaterials production equipment. Production program covers mostly antibacterial products for healthcare (patches, bandages), hygiene (insoles), cleaning and food industry. The company also produces unique machines for polymerisation of nanolayers at textile materials 'INM Foulard' and exclusively distributes unique patented electrospinning devices 'MultiSpin' and electrospinning devices clima control units 'ClimaSpin'.
Offers different microfluidic platforms that precisely manipulate different combinations of fluids to obtain jets, emulsions, bubbles, drops and particles in the nano and micrometric range.